Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer | Synapse

November 3, 2009

Ver artículo completo

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer

HLHumberto Lara-GuerraRegeneron (United States)TWThomas K. WaddellUniversity of New Brunswick ASAlexandra SalvarreyUniversity Health Network

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Preoperative window therapy with gefitinib is a safe and feasible regimen in early NSCLC and provides a trial design that may better inform predictors of treatment response or sensitivity.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Lara-Guerra et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcc30ed4d0de07d11339c5 https://doi.org/https://doi.org/10.1200/jco.2009.22.3370

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer2007 · 64 citations
2The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’ ) is not related to the expression of EGFR or HER-2 or to K-ras gene status2003 · 65 citations
3Une chimiothérapie adjuvante par mitomycine, cisplatine et vindésine n’améliore pas la survie de cancers bronchiques non à petites cellules opérés2004 · 65 citations
4Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST)2008 · 39 citations
5Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer2003 · 2,889 citations